证券代码：301234 证券简称：五洲医疗 公告编号：2025-039 安徽宏宇五洲医疗器械股份有限公司 股东关于减持股份达到 1%的公告 二、备查文件 1、《关于持股比例触及 1%整数倍的告知函》。 一、持股比例变动的具体情况 | 股票简称 | 五洲医疗 | | 股票代码 | 301234 | | | --- | --- | --- | --- | --- | --- | | 变动方向 | | 上升□ 下降☑ | 一致行动人 | 有☑ 无□ | | | 是否为第一大股东或实际控制人 | | | 是□ 否☑ | | | | 2、本次权益变动情况 | | | | | | | 股份种类 | | 减持股数（股） | | 减持比例（%） | | | 无限售条件普通股 | | 679,900 | | 1% | | | 合计 | | 679,900 | | 1% | | | 本次权益变动方式 | | 通过证券交易所的集中交易 | ☑ | | | | （可多选） | | 通过证券交易所的大宗交易 | ☑ | | | | | | 其他 | □ | | | | 3、本次变动前后，投资者及其一致行动人拥有上市公司权益的股份情况 ...

五洲医疗12月15日大宗交易平台共发生1笔成交，合计成交量10.00万股，成交金额386.60万元。成交价 格平均为38.66元，相对今日收盘价折价14.79%。 12月15日五洲医疗大宗交易一览 （以上内容为自选股写手差分机完成，仅作为用户看盘参考，不能作为操作依据。） 风险提示：以上内容仅作为作者或者嘉宾的观点，不代表和讯的任何立场，不构成与和讯相关的任何投 资建议。在作出任何投资决定前，投资者应根据自身情况考虑投资产品相关的风险因素，并于需要时咨 询专业投资顾问意见。和讯竭力但不能证实上述内容的真实性、准确性和原创性，对此和讯不做任何保 证和承诺。 | 成交量(万 | 成交金额(万 | 成交价格 | 买方营业 | 卖方营业部 | | --- | --- | --- | --- | --- | | 股) | 元) | (元) | 部 | | | 10.00 | 386.60 | 38.66 | 机构专用 | 光大证券股份有限公司合肥北一环路证券营业 | | | | | 部 | | ...

Core Viewpoint - Wuzhou Medical has seen a 4.44% increase in stock price, with a trading volume of 151 million yuan and a market capitalization of 3.085 billion yuan, indicating positive market sentiment towards the company [1] Group 1: Company Overview - Wuzhou Medical specializes in the research, production, and sales of disposable sterile infusion medical devices, including various types of syringes, infusion sets, blood transfusion devices, and other related medical supplies [2] - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which signifies its strong market position and innovation capabilities [2] - As of October 20, the company reported a revenue of 345 million yuan for the first nine months of 2025, reflecting a year-on-year growth of 0.82%, while the net profit attributable to shareholders decreased by 46.09% to 18.51 million yuan [7] Group 2: Financial Performance - The company’s overseas revenue accounts for 96.88% of total revenue, benefiting from the depreciation of the Chinese yuan [3] - The average trading cost of the stock is 42.55 yuan, with the current stock price fluctuating between resistance at 47.98 yuan and support at 43.15 yuan, suggesting potential for short-term trading strategies [6] - Wuzhou Medical has distributed a total of 81.6 million yuan in dividends since its A-share listing [8] Group 3: Market Activity - The stock has experienced a net inflow of 3.86 million yuan from major investors today, with a total of 95.76 million yuan net inflow in the industry over the past two days [4][5] - The stock's trading volume indicates a dispersed distribution of shares among major investors, with major transactions accounting for 7.61% of total trading volume [5]

Core Viewpoint - Wuzhou Medical has shown a slight increase in stock price and has been recognized as a "specialized, refined, distinctive, and innovative" enterprise, which enhances its competitive edge in the medical device industry [2][3]. Company Overview - Wuzhou Medical, established on April 15, 2011, and listed on July 5, 2022, specializes in the research, production, and sales of disposable sterile infusion medical devices and related medical supplies [7]. - The company's revenue composition includes 41.29% from syringes, 25.51% from medical puncture needles, 20.92% from infusion and blood transfusion devices, and 12.28% from other products [7]. - As of October 20, 2023, the company had 5,489 shareholders, an increase of 17.31%, with an average of 7,318 circulating shares per person, a decrease of 14.76% [7]. Financial Performance - For the period from January to September 2025, Wuzhou Medical achieved a revenue of 345 million yuan, representing a year-on-year growth of 0.82%, while the net profit attributable to the parent company was 18.51 million yuan, a decrease of 46.09% year-on-year [7]. - The company has distributed a total of 81.6 million yuan in dividends since its A-share listing [8]. Market Position and Trends - Wuzhou Medical's main business benefits from the depreciation of the RMB, with overseas revenue accounting for 96.88% of total revenue [3]. - The company is categorized under the pharmaceutical and biological industry, specifically in medical devices and consumables, and is part of several concept sectors including specialized and innovative enterprises, financing, and small-cap stocks [7]. Trading Activity - On December 12, 2023, Wuzhou Medical's stock rose by 0.91%, with a trading volume of 83.52 million yuan and a turnover rate of 4.81%, leading to a total market capitalization of 2.954 billion yuan [1]. - The stock has seen a net inflow of 8.06 million yuan from major investors, indicating a positive trend over the past three days [4][5]. Technical Analysis - The average trading cost of the stock is 42.39 yuan, with the current price approaching a support level of 43.15 yuan, suggesting potential for a rebound if this level holds [6].

证券日报网讯 12月10日晚间，五洲医疗发布公告称，公司拟使用任一时点余额不超过人民币38，000万 元的闲置自有资金进行委托理财，投资品种包括但不限于结构性存款、协议存单、通知存款、定期存 款、大额存单、收益凭证、国债逆回购、债券投资等安全性高、流动性好、风险较低的理财产品。 （编辑 丛可心） ...

Core Viewpoint - The company, Wuzhou Medical, is experiencing a decline in stock price and trading volume, while benefiting from its status as a "specialized, refined, distinctive, and innovative" enterprise and the depreciation of the RMB, which positively impacts its overseas revenue. Group 1: Company Overview - Wuzhou Medical specializes in the research, production, and sales of disposable sterile infusion medical devices and related medical supplies, including various types of syringes and infusion devices [2][7] - The company was established on April 15, 2011, and went public on July 5, 2022 [7] - As of October 20, the company had 5,489 shareholders, an increase of 17.31%, with an average of 7,318 circulating shares per person, a decrease of 14.76% [7] Group 2: Financial Performance - For the period from January to September 2025, Wuzhou Medical achieved a revenue of 345 million yuan, a year-on-year increase of 0.82%, while the net profit attributable to the parent company was 18.51 million yuan, a year-on-year decrease of 46.09% [7] - The company has distributed a total of 81.6 million yuan in dividends since its A-share listing [8] Group 3: Market Position and Trends - Wuzhou Medical is recognized as a "little giant" enterprise, which signifies its strong innovation capabilities and high market share in niche markets [2] - The company’s overseas revenue accounts for 96.88% of its total revenue, benefiting from the depreciation of the RMB [3] - The main business revenue composition includes syringes (41.29%), medical puncture needles (25.51%), and infusion and blood transfusion devices (20.92%) [7] Group 4: Technical Analysis - The average trading cost of the stock is 42.36 yuan, with recent accumulation activity noted, although the strength of this accumulation is weak [6] - The current stock price is near a resistance level of 43.15 yuan, indicating potential for a pullback unless this level is broken [6]

每经头条（nbdtoutiao）——白金信用卡权益大缩水：贵宾厅限次、酒店减量⋯⋯银行吐槽没赚头，"羊 毛党"薅了个寂寞 （记者 张明双） 每经AI快讯，五洲医疗（SZ 301234，收盘价：43.91元）12月10日晚间发布公告称，公司第三届第十一 次董事会会议于2025年12月10日在公司会议室召开。会议审议了《关于使用部分闲置自有资金委托理财 的议案》等文件。 2024年1至12月份，五洲医疗的营业收入构成为：医疗器械行业占比100.0%。 截至发稿，五洲医疗市值为30亿元。 ...

证券代码：301234 证券简称：五洲医疗 公告编号：2025-038 安徽宏宇五洲医疗器械股份有限公司 关于使用部分闲置自有资金委托理财的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或者重大遗漏。 重要内容提示： 1、投资种类：投资品种包括但不限于结构性存款、协议存单、通知存款、 定期存款、大额存单、收益凭证、国债逆回购、债券投资等安全性高、流动性好、 风险较低的理财产品； 2、投资金额：不超过人民币 38,000 万元元（含本数）； 3、特别风险提示：金融市场受宏观经济政策、经济走势等多方面影响，公 司将根据经济形势及金融市场的变化适时适量地介入相关产品，因此委托理财的 实际收益不可预期，敬请投资者注意投资风险。 安徽宏宇五洲医疗器械股份有限公司（以下简称"公司"）第三届董事会第 十一次会议审议通过了《关于使用部分闲置自有资金委托理财的议案》，同意在 确保不影响公司及子公司正常生产经营和确保资金安全的情况下，使用任一时点 余额不超过人民币 38,000 万元的闲置自有资金进行委托理财。上述委托理财额 度自公司董事会审议通过之日起 12 个月内可以循环滚动使用， ...

使用部分闲置自有资金委托理财的核查意见 光大证券股份有限公司关于安徽宏宇五洲医疗器械股份有限公司 光大证券股份有限公司（以下简称"光大证券""保荐机构"）作为安徽宏 宇五洲医疗器械股份有限公司（以下简称"五洲医疗""公司"）持续督导的保 荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交易所创业板股票 上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》等有关规定，就五洲医疗使用部分闲置自有资金委托理财的事项进行 了核查，具体情况如下： 一、本次使用部分闲置自有资金委托理财的基本情况 （一）投资目的 在不影响公司及子公司正常生产经营和确保资金安全的情况下，合理使用部 分闲置自有资金开展委托理财，提高公司资金使用效率，增加资金投资收益，为 公司获取更多投资回报。 （二）投资额度 公司及子公司拟使用任一时点余额不超过人民币 38,000 万元闲置自有资金开 展委托理财，在上述额度范围内，资金可以循环滚动使用，但任一时点的委托理 财金额（含前述投资的收益进行再投资的相关金额）不应超过投资额度。 （三）投资方式 公司拟使用闲置自有资金投资于安全性高、流动性好、风险较低的理财产品 ...

公司董事会同意使用任一时点余额不超过人民币 38,000 万元的闲置自有资 金开展委托理财，在上述额度及期限内，资金可以滚动使用。并授权公司董事长 或其授权代表在上述额度和期限范围内行使相关审批权限，签署相关合同或法律 文件，并由公司财务部负责具体办理相关事宜。 表决结果：同意 7 票，反对 0 票，弃权 0 票，回避 0 票。 安徽宏宇五洲医疗器械股份有限公司 第三届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 安徽宏宇五洲医疗器械股份有限公司（以下简称"公司"）第三届董事会第 十一次会议于 2025 年 12 月 10 日以现场结合通讯方式在公司会议室召开，会议 于 2025 年 12 月 1 日以书面和通讯方式通知全体董事。本次会议应出席董事 7 名，实际出席董事 7 名。 本次会议由公司董事长黄凡先生主持，公司高级管理人员列席了会议。会议 的召开符合《公司法》等法律法规、规范性文件和《公司章程》的规定。 二、董事会会议审议情况 1、审议通过《关于使用部分闲置自有资金委托理财的议案》 证券代码：30 ...